NCT05103917View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

November 24, 2022

Study Completion Date

May 21, 2023

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

X4P-001

CXCR4 inhibitor

Trial Locations (1)

200032

Shang hai Tumor Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY